Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations.

Biochemical and biophysical research communications - 12 Nov 2020

Kayatani Hiroe, Ohashi Kadoaki, Ninomiya Kiichiro, Makimoto Go, Nishii Kazuya, Higo Hisao, Watanabe Hiromi, Kano Hirohisa, Kato Yuka, Ninomiya Takashi, Kubo Toshio, Rai Kammei, Ichihara Eiki, Hotta Katsuyuki, Tabata Masahiro, Maeda Yoshinobu, Kiura Katsuyuki

Abstract excerpt

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the standard therapy for non-small cell lung cancer (NSCLC) harboring EGFR mutations, but the resistance is inevitable. The drug-tolerant persister cancer cells are thought to be involved in the resistance. We recently reported that HER2 expression had a negative impact on time-to-treatment-failure in patients with EGFR mutant NSCLC. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Protein Kinase Inhibitors

Share to Receptor, ErbB-2

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 32888648
DOI: 10.1016/j.bbrc.2020.07.055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations.PMID 32888648Read ↗

Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review.Semantic proximity Read ↗

The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.Semantic proximity Read ↗

Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors.Semantic proximity Read ↗

Continued EGFR-TKIs treatment promotes the survival of elderly patients with acquired resistance to EGFR-TKIs therapy.Semantic proximity Read ↗

Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancerSemantic proximity Read ↗

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations.Semantic proximity Read ↗

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC.Semantic proximity Read ↗

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.Semantic proximity Read ↗

The Crosstalk Mechanism of EGFR and ER in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation.Semantic proximity Read ↗

Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.Semantic proximity Read ↗

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.